2017 – Page 33 – Policy & Medicine

Politico Healthcare Briefing: What’s Next for Drug Costs?

FDA Extends Wait for Biosimilar Interchangeability Guidance

FDA Releases Draft Guidance on Manufacturer Communications with Payors, Formulary Committees, and Similar Entities

Final Common Rule – Sixteen Agencies Update Regulations on Individuals Who Participate in Human Research

Not All Discounts Are Equal: Evaluating When Discounts May Be Construed as Unlawful

FDA Releases Draft Guidance for Medical Product Communications Consistent with FDA-Required Labeling

FDA Releases Draft Guidance for Industry on Biosimilar Interchangeability

U.S. Senators Collins and McCaskill Release Drug Pricing Investigation Report

Nursing Facilities & Kickbacks – Is the DOJ Shifting Away from Pharma?

The Trump Administration: One Predictive Perspective